Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Total Debt came in at $115.8 million in Q4 2025, up 22.41% YoY from $94.6 million in Q4 2024, and up 20.14% on a QoQ basis from $96.4 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 2 years of Total Debt data on file, last reported at $115.8 million in Q4 2025.
- Quarterly Total Debt rose 22.41% year-over-year to $115.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $115.8 million (up 22.41% YoY) and the FY2025 annual result came in at $115.8 million, up 22.41% from the prior year.
- Total Debt climbed to $115.8 million in Q4 2025, from $96.4 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $115.8 million in Q4 2025 to a low of $93.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 9.34 Bn |
| 10 | Karyopharm Therapeutics | 55.71 Mn | 55.71 Mn | 32.35 Mn | 125.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.35 Mn |
| Dec 31, 2025 | 115.81 Mn |
| Sep 30, 2025 | 96.40 Mn |
| Jun 30, 2025 | 95.82 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 94.60 Mn |
| Sep 30, 2024 | 94.11 Mn |
| Jun 30, 2024 | 93.52 Mn |